State Key Laboratory of Experimental Hematology & National Clinical Research Center for Blood Disease, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
The Postdoctoral Research Station, School of Medicine, Nankai University, Tianjin, China.
Cell Prolif. 2020 Aug;53(8):e12862. doi: 10.1111/cpr.12862. Epub 2020 Jun 29.
Longitudinal studies have indicated VCAM-1 mesenchymal stem/stromal cells (MSCs) as promising resources in regenerative medicine, yet the abundance in gene expression is far from adequate in the advantaged and "discarded" hUC-MSCs. Thus, high-efficient preparation and systematic dissection of the signatures and biofunctions of the subpopulation is the prerequisite for large-scale clinical applications.
We primarily took advantage of a cytokine-based programming strategy for large-scale VCAM-1 hUC-MSC generation (III-MSCs). Thereafter, we conducted multifaceted analyses including cytomorphology, immunophenotype, cell vitality, multilineage differentiation, whole-genome analysis, tube formation and Matrigel plug assay, lymphocyte activation and differentiation, and systemic transplantation for aplastic anaemia (AA) treatment.
III-MSCs with high-proportioned VCAM-1 expression were obtained by combining IL-1β, IL-4 with IFN-γ, which exhibited comparable immunophenotype with untreated hUC-MSCs (NT-MSCs) but revealed multidimensional superiorities both at the cellular and molecular levels. Simultaneously, systemic infusion of III-MSCs could significantly ameliorate clinicopathological features and finally help facilitate haematopoietic reconstruction and immunoregulation in AA mice.
We have established a high-efficient procedure for large-scale generation of III-MSCs with preferable signatures and efficacy upon aplastic anaemia in mice. Our findings suggested that III-MSCs were advantageous sources with multifaceted characteristics for regenerative medicine.
纵向研究表明 VCAM-1 间充质干细胞(MSCs)是再生医学中有前途的资源,但在优势和“废弃”的 hUC-MSCs 中,其基因表达的丰度还远远不够。因此,高效制备和系统剖析亚群的特征和生物功能是大规模临床应用的前提。
我们主要利用基于细胞因子的编程策略来大规模生成 VCAM-1 hUC-MSC(III-MSCs)。此后,我们进行了多方面的分析,包括细胞形态学、免疫表型、细胞活力、多系分化、全基因组分析、管形成和 Matrigel 塞植入检测、淋巴细胞激活和分化以及系统性移植治疗再生障碍性贫血(AA)。
通过将 IL-1β、IL-4 与 IFN-γ 结合,获得了高比例表达 VCAM-1 的 III-MSCs,其免疫表型与未经处理的 hUC-MSCs(NT-MSCs)相似,但在细胞和分子水平上均具有多维优势。同时,全身性输注 III-MSCs 可显著改善临床病理特征,最终有助于促进 AA 小鼠的造血重建和免疫调节。
我们已经建立了一种高效的程序,可以大规模生成具有更好特征和疗效的 III-MSCs,用于治疗小鼠再生障碍性贫血。我们的研究结果表明,III-MSCs 是一种具有多方面特征的再生医学优势来源。